Cargando...
Anaplastic Lymphoma Kinase (ALK) as a therapeutic target in non-small cell lung cancer
The therapeutic targeting of anaplastic lymphoma kinase (ALK) has been a burgeoning area of research since 2007 when ALK fusions were initially identified in patients with non-small cell lung cancer (NSCLC). The field has rapidly progressed through development of the first-generation ALK inhibitor,...
Guardado en:
| Publicado en: | Cancer J |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5242382/ https://ncbi.nlm.nih.gov/pubmed/26389762 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000142 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|